• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

    2/14/23 4:05:43 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRPX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    VIRPAX PHARMACEUTICALS, Inc.
    (Name of Issuer)
     
    COMMON STOCK, PAR VALUE $0.00001 PER SHARE
    (Title of Class of Securities)
     
    928251107
    (CUSIP Number)
     
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 928251107
    (1) Names of Reporting Persons
      Anthony P. Mack  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐  
      (b) ☐  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 3,080,566*  
      (6) Shared Voting Power: 0*  
      (7) Sole Dispositive Power: 3,080,566*  
      (8) Shared Dispositive Power: 0*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      3,080,566*  
    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
      ☐  
    (11) Percent of Class Represented by Amount in Row (9)
      26.1%*  
    (12) Type of Reporting Person
      IN  
    * See Item 4 for additional information.

     

     
     

     

    CUSIP No. 928251107
    (1) Names of Reporting Persons
      Virpax Pharmaceuticals, LLC  
    (2) Check the Appropriate Box if a Member of a Group (a) ☐  
      (b) ☐  
         
    (3) SEC Use Only
    (4) Citizenship or Place of Organization
      United States  
    Number of Shares Beneficially Owned By Each Reporting Person With
      (5) Sole Voting Power: 2,730,438*  
      (6) Shared Voting Power: 0*  
      (7) Sole Dispositive Power: 2,730,438*  
      (8) Shared Dispositive Power: 0*  
           
    (9) Aggregate Amount Beneficially Owned by Each Reporting Person
      2,730,438*  
    (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
      ☐  
    (11) Percent of Class Represented by Amount in Row (9)
      23.3%*  
    (12) Type of Reporting Person
      OO  
    * See Item 4 for additional information.

     

     
     

     

    Item 1(a). Name Of Issuer:

     

    Virpax Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1055 Westlakes Drive, Suite 300

    Berwyn, PA 19312

     

    Item 2(a). Name of Person Filing:

     

    This report on Schedule 13G (this “Schedule 13G”) is being filed by (i) Anthony P. Mack (“Mr. Mack”) and (ii) Virpax Pharmaceuticals, LLC (“Virpax LLC” together with Mr. Mack, the “Reporting Persons”).

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The address for the Reporting Persons is:

     

    C/O Virpax Pharmaceuticals, Inc.

    1055 Westlakes Drive, Suite 300

    Berwyn, PA 19312

     

    Item 2(c). Citizenship:

     

    Mr. Mack is a citizen of the United States. Virpax LLC is a limited liability company organized under the laws of the state of Delaware.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.00001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP No.:

     

    928251107

     

    Item 3. If This Statement Is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

     

    Not Applicable.

     

     
     

     

    Item 4. Ownership:

     

    As reported in the cover page to this report, the ownership information with respect to Mr. Mack is as follows:

     

      (a) Amount Beneficially Owned: 3,080,566*
      (b) Percent of Class: 26.1%*
      (c) Number of Shares as to which such person has:  
        (i) sole power to vote or to direct the vote: 3,080,566*
        (ii) shared power to vote or to direct the vote: 0*
        (iii) sole power to dispose or to direct the disposition of: 3,080,566*
        (iv) shared power to dispose or to direct the disposition of: 0*

     

    As reported in the cover page to this report, the ownership information with respect to Virpax LLC is as follows:

     

      (a) Amount Beneficially Owned: 2,730,438*
      (b) Percent of Class: 23.3%*
      (c) Number of Shares as to which such person has:  
        (i) sole power to vote or to direct the vote: 2,730,438*
        (ii) shared power to vote or to direct the vote: 0*
        (iii) sole power to dispose or to direct the disposition of: 2,730,438*
        (iv) shared power to dispose or to direct the disposition of: 0*

     

    * Mr. Mack is the Chief Executive Officer of the Issuer. Mr. Mack owns 88.8888% of the outstanding member units of Virpax LLC, and he may be deemed to have sole voting and dispositive control over the shares of Common Stock held by Virpax LLC. As a result, Mr. Mack may be deemed to beneficially own the shares of Common Stock held by Virpax LLC.

     

    As of December 31, 2022, Mr. Mack, as the managing member of Virpax LLC, may be deemed to beneficially own (i) 2,730,438 shares of Common Stock held directly by Virpax LLC, (ii) 252,562 shares of Common Stock held directly by Mr. Mack, and (ii) 97,566 shares of Common Stock issuable upon exercise of stock options that are exercisable within 60 days of December 31, 2022. Mr. Mack also owns 73,785 shares of Common Stock issuable upon exercise of stock options that are not exercisable within 60 days of December 31, 2022. As a result, Mr. Mack is deemed not to beneficially own any shares of Common Stock underlying these options.

     

    The reported beneficial ownership percentage is based upon 11,714,434 shares of Common Stock issued and outstanding as of November 8, 2022, based on information reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2022.

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group:

     

    Not Applicable.

     

    Item 10. Certification:

     

    Not applicable.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2023  
           
      VIRPAX PHARMACEUTICALS, LLC  
           
      By: /s/ Anthony P. Mack  
      Name: Anthony P. Mack  
      Title: Managing Member  
                                                                                
        /s/ Anthony P. Mack  
        Anthony P. Mack  

     

    Attention: Intentional misstatements or omissions of fact constitute

    Federal criminal violations (See 18 U.S.C. 1001)

     

     
     

     

    Exhibit Index

     

    Exhibit

     

    1 Joint Filing Agreement, dated as of February 14, 2022, by and between Virpax Pharmaceuticals, LLC and Anthony P. Mack (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2022)

     

     

     

     

    Get the next $VRPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VRPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Virpax Pharmaceuticals Announces Reverse Stock Split

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 ("Effective

      3/19/25 8:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Pr

      3/18/25 4:01:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune

      3/7/25 8:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

      GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

      11/5/24 8:30:00 AM ET
      $ADIL
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Announces Leadership Transition

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that due to ongoing litigation it has accepted the resignation of Anthony P. Mack as CEO and Chairman effective immediately. The Board has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has served as the Company's Executive Vice President of Commercial Operations since August 2017, as a member of the Company's Board since July 2021 and as the President and CEO of the Company's wholly owned su

      11/17/23 7:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics,

      3/28/23 8:58:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Panis Jaydriane

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      1/8/25 4:11:17 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Chaudhry Usama

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      1/6/25 4:05:29 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Randhawa Esha

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      12/4/24 8:30:14 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

      SC 13G - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      5/23/24 4:06:37 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      1/2/24 10:11:28 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      2/14/23 4:05:43 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Financials

    Live finance-specific insights

    See more
    • Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

      5/13/24 4:10:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Year-End Results

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

      3/26/24 7:30:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

      11/15/23 4:15:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    SEC Filings

    See more
    • Amendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      4/3/25 5:00:46 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      4/3/25 11:00:41 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.

      S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      3/25/25 6:10:49 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care